Nuvation Bio completed the acquisition of Decheng Capital-backed AnHeart Therapeutics for $145m.

Nuvation Bio, a biopharmaceutical company, completed the acquisition of Decheng Capital-backed AnHeart Therapeutics, a clinical-stage global biopharmaceutical company developing a pipeline of novel precision oncology therapeutics, for $145m. “The closing of the acquisition transforms Nuvation Bio into a late-stage, global oncology company that is well-capitalized and positioned to develop our newly expanded pipeline as we move toward becoming a commercial organization. We welcome the AnHeart team and look forward to leveraging our combined expertise to bring new cancer therapies to patients who need them most," David Hung, Nuvation Bio Founder, President, and CEO.